S
Synageva BioPharma
Discovering, developing, and delivering innovative medicines for people living with rare diseases of high unmet medical need
About Synageva BioPharma
Synageva BioPharma Corp. operated as a biopharmaceutical firm concentrated on the discovery, development, and commercialization of therapeutic products for patients with rare and devastating diseases. The company was originally incorporated as AviGenics, Inc. in 1996, founded by Dr. Robert Ivarie of the University of Georgia. A significant shift in strategy occurred in 2008 when Sanj K. Patel, a former executive at Genzyme Corporation, was brought in as CEO. Patel refocused the company on developing treatments for rare diseases, moving away from its initial business of creating bio-similar drugs.
The company's core asset was a proprietary technology platform utilizing a transgenic Gallus expression system to produce recombinant DNA proteins in the egg whites of genetically engineered chickens. This method allowed for the creation of proteins with specific glycan structures crucial for targeted cell delivery. Synageva went public on the NASDAQ in November 2011 through a reverse merger with Trimeris, Inc. The company’s primary business model was centered on developing a pipeline of protein-based therapies for rare diseases with unmet medical needs and bringing them to market.
Synageva's lead product candidate was Kanuma® (sebelipase alfa), an enzyme replacement therapy designed to treat Lysosomal Acid Lipase Deficiency (LAL-D), a rare and often fatal genetic disorder. LAL-D causes a buildup of fatty material in the liver, blood vessels, and other tissues. Before its acquisition, Synageva was preparing for the global launch of Kanuma, which had received priority review status from the FDA and accelerated assessment from the European Medicines Agency. In addition to Kanuma, the company's clinical pipeline included SBC-103, an enzyme replacement therapy for patients with mucopolysaccharidosis IIIB (MPS IIIB), and over 30 preclinical programs.
In a landmark deal for the biotech sector, Alexion Pharmaceuticals announced its acquisition of Synageva in May 2015 for approximately $8.4 billion. The acquisition, which was unanimously approved by both boards and completed in June 2015, was a strategic move by Alexion to strengthen its global leadership in rare diseases and diversify its revenue streams. The price represented a premium of about 140% over Synageva's share price at the time, underscoring the perceived value of its pipeline, especially Kanuma. Following the acquisition, the FDA approved Kanuma in December 2015.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1996
- Headquarters
- Lexington, United States
- Listing
- IPO 2011
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2015 | $8.4B | $8.4B | Alexion Pharmaceuticals | — |
| POST IPO EQUITYOther financing | Jan 2015 | $308M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Synageva BioPharma is 2.5K monthly website visits, up 900% over the last three months. Synageva BioPharma's team declined 9.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Synageva BioPharma in the Lexington ecosystem
The Synageva BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
- CVCordova Ventures
- FVFuqua Ventures
- KCKitty Hawk Capital
Four Partners
Tullis Health Investors
New Leaf Venture Partners- YDYasuda Enterprise Development
Covera Ventures
Other known investors1 additional known investor
Alexion Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synageva BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synageva BioPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










